Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 9/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704067 | 1.00 | SYK (0.58) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2955816 | 1.00 | SYK (0.58) | SYKCTSKCTSSCTSLCTSB | |
| Hydrochloric Acid SCHEMBL7444521 | 0.99 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| Hydrochloric Acid SCHEMBL7444525 | 0.99 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL8257062 | 0.90 | PPARA (0.58) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL20885273 | 0.90 | PPARA (0.58) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL11127997 | 0.88 | SYK (0.66) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL21340066 | 0.88 | SYK (0.66) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL19485480 | 0.88 | CTSK (0.62) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL6320951 | 0.88 | SYK (0.59) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171026-B | Production intermediate for nitrogen-containing compound or salt thereof | 富士胶片株式会社 | 2023-03-03 | — | — | CN | disclosed |
| CN-110167933-B | As αVAzole amides and amines as integrin inhibitors | 百时美施贵宝公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3275883-B1 | METHOD FOR PRODUCING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, AND PRODUCTION INTERMEDIATE OF SAME | FUJIFILM CORP (JP) | 2021-06-02 | — | — | EP | disclosed |
| CN-111171026-A | Production intermediate for nitrogen-containing compound or salt thereof | 富士胶片株式会社 | 2020-05-19 | — | — | CN | disclosed |
| CN-107428755-B | Process for producing nitrogen-containing compound or salt thereof, and intermediate for production thereof | 富士胶片株式会社 | 2020-03-03 | — | — | CN | disclosed |
| EP-3275883-A1 | METHOD FOR PRODUCING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, AND PRODUCTION INTERMEDIATE OF SAME | FUJIFILM Corporation (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-8765766-B2 | Pyrimidine derivatives which are antagonists of the vitronectin receptor | GALAPAGOS NV (BE) | 2014-07-01 | — | — | US | disclosed |
| EP-0854140-B1 | Vitronectin receptor antagonists, their production and their use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2012-05-10 | — | — | US | disclosed |
| US-8133896-B2 | Pyrimidine derivatives which are antagonist of the vitronectin receptor | GALAPAGOS NV (BE) | 2012-03-13 | — | — | US | disclosed |
| EP-1049693-A1 | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-11-08 | — | — | EP | disclosed |
| US-6011045-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT | 2000-01-04 | — | — | US | disclosed |
| WO-1999026945-A1 | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999020606-A2 | PIPERIDINES AND PIPERAZINES AS PLATELET AGGREGATION INHIBITORS | J. URIACH & CIA. S.A. (ES) | 1999-04-29 | — | — | WO | disclosed |
| CN-1200374-A | Vitronectin receptor antagonists, their preparation and use | HOECHST AG (DE) | 1998-12-02 | — | — | CN | disclosed |
| EP-0854140-A2 | Vitronectin receptor antagonists, their production and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-22 | — | — | EP | disclosed |
| US-5760028-A | TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5710159-A | IMIDAZOLIN-2-YLAMINOPROPOXY)ISOXAZOL-5-CARBONYLAMINO-2 -BENZYLOXYCARBONYLAMINOPROPIONIC ACID AS ANTIINFLAMMATORY AGENTS, BONE DEGRADATION, TUMORS, METASTASES AND THROMBOSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| US-5646000-A | FLUORESCENT PROBES FOR INDENTIFYING ANTIPLATELET AGENTS | MERCK & CO., INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996010181-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING ACTIVATED PLATELETS | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | SYK 2736/4885CTSK 3066/4885CTSS 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.